A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

ACOs should worry about their overall Medicare strategy, not just Pathways to Success shared savings

by Mark Bethke, FSA, MAAA, Managing Director, Deloitte Consulting LLP

Prior to the Pathways to Success final rule, some people worried that proposed changes would begin to steer providers away from the Medicare Shared Savings Program. Instead, we believe the final rule—which the US Centers for Medicare and Medicaid announced December 21—actually strengthens the program by accelerating the transition to risk and promoting the shift to Medicare Advantage (MA).

Read more

The pursuit of value-based care is a marathon, and many health systems need to pick up the pace

by Wendy Gerhardt, Senior Manager, Deloitte Center for Health Solutions, Deloitte Services LP

I recently attended the 3rd Annual Value-Based Care Summit in Boston. I always love visiting Bean Town (baseball, lobster rolls, clam chowder, the Boston Marathon). But I was particularly excited to get into the meaty discussions at the conference. It has been three years since the Medicare Access and CHIP Reauthorization Act (MACRA) went into effect.

Read more

Portfolio optimization could help medtech navigate a perfect storm

by Mark Fedro, principal, Deloitte Consulting LLP and Luis Hakim, senior manager, Deloitte Consulting LLP

Years of growth through acquisition has resulted in a number of large players in the medtech space. Many companies that didn’t appropriately integrate the acquired companies (or their products) are now finding it difficult to effectively manage their extensive and complex product portfolios, which could be restricting their margins and their ability to invest and innovate.

Read more

The five Cs of disruption

by Pete Micca, Partner, Deloitte & Touche LLP

What’s shaping the future of health tech investment?


Health care technology investment in 2017 appeared to be all about convergence. In fact, there were no health tech IPOs at all that year.1 The focus seemed to be squarely on expanding industry footprints to gain economies of scale and more control over the continuum of health services.

Read more

Medtech companies can add value by uprooting low-value care

by Glenn Snyder, Principal, MedTech Practice Leader, Deloitte Consulting LLP

I’m headed to Philadelphia next week to moderate a panel of medtech CEOs at AdvaMed’s annual conference. Our topic: strategies to reduce low-value care. This is an important issue not just for medtech leaders, but for all health care stakeholders. The cost of low-value care is staggering. In the US alone, medical services that don’t necessarily benefit the patient top $200 billion annually.1

What is low-value care?

Read more